Research programme: osteoarthritis therapeutics - ProStrakan/TiGenixAlternative Names: BMP activators - ProStrakan/TiGenix; Bone morphogenetic protein activators - ProStrakan/TiGenix
Latest Information Update: 19 Sep 2007
At a glance
- Originator ProStrakan; TiGenix
- Class Small molecules
- Mechanism of Action Bone morphogenetic protein activators; Osteoblast stimulants; Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 19 Apr 2006 Preclinical development is ongoing